Review
Chemistry, Medicinal
Sorayya Ghasemi, Suowen Xu, Seyed Mohammad Nabavi, Mohammad Amir Amirkhani, Antoni Sureda, Silvia Tejada, Zahra Lorigooini
Summary: Epigenetic alterations play a significant role in cancer development, especially in cancer stem cells (CSCs). Epigenetic therapies targeting CSCs are emerging as a promising strategy for cancer treatment, with phenolic compounds potentially neutralizing CSCs development and metabolism through epigenetic mechanisms.
PHYTOTHERAPY RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Arianna Casciati, Mirella Tanori, Isabella Gianlorenzi, Elena Rampazzo, Luca Persano, Giampietro Viola, Alice Cani, Silvia Bresolin, Carmela Marino, Mariateresa Mancuso, Caterina Merla
Summary: Glioblastoma multiforme (GBM) is the most common brain cancer in adults, and current therapies have limited effectiveness. Research has shown that high intensity ultra-short pulsed electric fields (PEFs) can affect the growth and differentiation of GBM cells and neurospheres, potentially providing a promising treatment option.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Amirhossein Izadpanah, Niloufar Mohammadkhani, Mina Masoudnia, Mahsa Ghasemzad, Arefeh Saeedian, Hamid Mehdizadeh, Mansour Poorebrahim, Marzieh Ebrahimi
Summary: Accumulating data has shown that cancer stem cells (CSCs) play a crucial role in tumor metastasis and recurrence. Targeting CSC-related signaling pathways and surface markers could help eradicate tumors and improve cancer survival. Immunotherapy strategies, such as dendritic cell (DC) vaccines, chimeric antigen receptors (CAR)-engineered immune cells, and monoclonal antibodies (mAbs), have shown promising results in targeting CSCs.
Review
Pharmacology & Pharmacy
Bandana Chakravarti, Jawed Akhtar Siddiqui, Rohit Anthony Sinha, Sana Raza
Summary: Cancer stem cells (CSCs) are a subset of cancer cells that possess the ability to self-renew and initiate tumors. CSCs exhibit resistance to traditional therapies and are a major driver of disease relapse. Recent studies have revealed that CSCs have distinct metabolic properties, and metabolic reprogramming plays a crucial role in their self-renewal and maintenance.
BIOCHEMICAL PHARMACOLOGY
(2023)
Review
Chemistry, Multidisciplinary
Shuai Lv, Yufei Liu, Changheng Xie, Chenyang Xue, Shi Du, Jing Yao
Summary: Tumor angiogenesis and cancer stem cells are two major features of solid tumors that have critical roles in tumor progression, metastasis, and recurrence. There is evidence of a close association between cancer stem cells and tumor vasculature, where cancer stem cells promote tumor angiogenesis and the highly vascularized tumor microenvironment further maintains their growth, forming a vicious circle to promote tumor development. This review highlights the crosstalk between tumor vasculature and cancer stem cells, with emphasis on small-molecule compounds and associated biological signaling pathways. Disrupting the cancer stem cells-angiogenesis vicious circle by linking tumor vessels to cancer stem cells is of utmost importance, and more precise treatment regimens targeting tumor vasculature and cancer stem cells are expected to improve future tumor treatments.
JOURNAL OF CONTROLLED RELEASE
(2023)
Review
Biochemistry & Molecular Biology
Bo Wu, Xiang Shi, Meixi Jiang, Hongxu Liu
Summary: Ongoing research has revealed that the existence of cancer stem cells (CSCs) is a major obstacle in current cancer therapy. CSCs play a significant role in tumor progression, recurrence, and chemoresistance due to their stemness characteristics. CSCs interact with the tumor microenvironment through complex mechanisms, and also engage in interactions with immune cells and molecules to protect themselves against immune clearance. Understanding these interactions may provide novel therapeutic approaches to cancer.
Review
Biology
Ilias Tsochantaridis, Angelos Roupas, Sofie Mohlin, Aglaia Pappa, Georgia-Persephoni Voulgaridou
Summary: Cancer is a complex and multifactorial disease with high phenotypic plasticity and diversity. Intratumoral heterogeneity, caused by the presence of cancer stem cells (CSCs) with stem-like properties, poses a major challenge in cancer treatment. CSCs exhibit enhanced chemoresistance and the identification of specific CSC biomarkers, such as ALDH1B1, is crucial for effective clinical therapies.
Review
Oncology
Mehmet Gunduz, Esra Gunduz, Shunji Tamagawa, Keisuke Enomoto, Muneki Hotomi
Summary: Although progress has been made in understanding cancer stem cells, particularly in oropharyngeal cancer, much remains unknown. These stem cells play roles in tumor invasion, metastasis, drug resistance, and recurrence, but there are still many unanswered questions.
Article
Medicine, Research & Experimental
Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, Abilash Valsala Gopalakrishnan, Pragya Bradu, Aarthi Sukumar, Megha Patil, Kaviyarasi Renu, Abhijit Dey, Balachandar Vellingiri, Alex George, Raja Ganesan
Summary: This review provides a detailed study on pancreatic cancer and its association with different types of cancer related to diabetes. It discusses the combination of anti-diabetic drugs with other anti-cancer drugs and phytochemicals for the prevention and treatment of the disease. The migration and development of pancreatic cancer stem cells (CSCs) are also discussed. Additionally, it explores the mechanisms of diabetes development that enhance the proliferation of pancreatic CSCs, such as increased IGF factor levels, epigenetic modifications, DNA damage, and lifestyle factors like obesity and inflammation.
Review
Biochemistry & Molecular Biology
Zhen Zeng, Minyang Fu, Yuan Hu, Yuquan Wei, Xiawei Wei, Min Luo
Summary: This article reviews the origin, biological characteristics, and regulatory networks of cancer stem cells (CSCs), discusses the factors influencing therapy resistance in CSCs, and introduces some treatment strategies specifically targeting CSCs.
Review
Medicine, General & Internal
Elisa Stellaria Grassi, Viola Ghiandai, Luca Persani
Summary: Recent studies have shown intratumoral heterogeneity in thyroid cancer, with cancer stem-like cells hypothesized to drive tumor heterogeneity, contributing to its metastatic potential and therapy resistance. These cancer stem cells primarily exist in specific tumor areas, known as stem cell niches.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Cell Biology
Chiara Donini, Ramona Rotolo, Alessia Proment, Massimo Aglietta, Dario Sangiolo, Valeria Leuci
Summary: The term cancer stem cells (CSCs) refers to tumor cells with stemness features that may contribute to chemo-resistance and disease relapses, with potential susceptibility to immune system recognition and targeting. Cellular immunotherapies, including those using chimeric antigen receptors (CAR) for genetic redirection, show promise for selective elimination of CSC subsets in different tumor settings. Preclinical studies support the potential targeting of CSCs by cellular immunotherapies, with ongoing clinical studies and new opportunities for T and non-T antitumor lymphocytes.
Review
Biochemistry & Molecular Biology
Silvia Mara Baez Rodriguez, Georgiana-Adeline Staicu, Ani-Simona Sevastre, Carina Baloi, Vasile Ciubotaru, Anica Dricu, Ligia Gabriela Tataranu
Summary: Glioblastoma stem cells (GSCs) are self-renewing cells that can initiate tumors and are linked to tumor heterogeneity. Standard treatments fail to eradicate GSCs, leading to disease recurrence. Understanding the biology and survival mechanisms of GSCs is crucial for targeting them effectively.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Cell Biology
Karina Biserova, Arvids Jakovlevs, Romans Uljanovs, Ilze Strumfa
Summary: Cancer stem cells, particularly in glioblastoma, play a crucial role in tumor resistance to treatment and recurrence. The regulatory mechanisms of glioma stem cells include tumor microenvironment, niche concept, metabolism, immunity, genetics, and epigenetics, which serve as potential targets for future treatments.Understanding the molecular markers and treatment resistance of GSCs in glioblastoma may lead to more effective therapeutic strategies in the future.
Article
Biochemistry & Molecular Biology
Tao Huang, Jae Sam Lee, Alexander L. Klibanov, Jiang He
Summary: The therapeutic effect of Lu-177-labeled immunoliposomes on CSCs of mesothelioma was evaluated in this study. The results showed that Lu-177-ILs inhibited proliferation, promoted apoptosis, and suppressed the expression of CD26 and CD24. Therefore, molecular radiotherapy targeting both CD26 and CD24 could be a promising approach for CSC-targeting therapy for MM.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Medicinal
Nathalie M. Grob, Sarah Schmid, Roger Schibli, Martin Behe, Thomas L. Mindt
JOURNAL OF MEDICINAL CHEMISTRY
(2020)
Article
Chemistry, Medicinal
Nathalie M. Grob, Daniel Haussinger, Xavier Deupi, Roger Schibli, Martin Behe, Thomas L. Mindt
JOURNAL OF MEDICINAL CHEMISTRY
(2020)
Article
Biochemistry & Molecular Biology
Martin Spillmann, Larissa Thurner, Nina Romantini, Mirjam Zimmermann, Benoit Meger, Martin Behe, Maria Waldhoer, Gebhard F. X. Schertler, Philipp Berger
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)
Article
Radiology, Nuclear Medicine & Medical Imaging
Marco F. Taddio, Claudia A. Castro Jaramillo, Peter Runge, Alain Blanc, Claudia Keller, Zeynep Talip, Martin Behe, Nicholas P. van der Meulen, Cornelia Halin, Roger Schibli, Stefanie D. Kramer
Summary: The study revealed that CD80 and CD86 are upregulated in LPS-induced local inflammation, indicating invasion of activated APCs. Cu-64-NODAGA-abatacept PET technology allows for tracking APC activation over time.
MOLECULAR IMAGING AND BIOLOGY
(2021)
Article
Chemistry, Medicinal
Nathalie M. Grob, Roger Schibli, Martin Behe, Ibai E. Valverde, Thomas L. Mindt
Summary: 1,5-Disubstituted 1,2,3-triazoles are bioisosteres of cis-amide bonds and have been shown to enhance pharmacological properties of peptides, particularly in improving receptor binding affinity and tumor uptake as illustrated in this study.
ACS MEDICINAL CHEMISTRY LETTERS
(2021)
Article
Multidisciplinary Sciences
Nina Romantini, Shahidul Alam, Stefanie Dobitz, Martin Spillmann, Martina De Foresta, Roger Schibli, Gebhard F. X. Schertler, Helma Wennemers, Xavier Deupi, Martin Behe, Philipp Berger
Summary: This study demonstrates that using rigid oligoproline backbones can develop ligands with biased GPCR signaling, and stabilizing GPCR dimers by fixing the distance between their recognition motifs can expand the space for medicinal chemistry.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Nic Gillings, Olaug Hjelstuen, Martin Behe, Clemens Decristoforo, Philip H. Elsinga, Valentina Ferrari, Oliver C. Kiss, Petra Kolenc, Jacek Koziorowski, Peter Laverman, Thomas L. Mindt, Meltem Ocak, Marianne Patt, Sergio Todde, Almut Walte
Summary: This document serves as a supplement to the EANM Guidelines on current Good Radiopharmacy Practice (cGRPP) and provides instructions for managing risks associated with small-scale in-house preparation of radiopharmaceuticals.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Oncology
Nicolo Rigamonti, Niina Veitonmaeki, Clara Domke, Sophie Barsin, Sarah Jetzer, Omar Abdelmotaleb, Ralph Bessey, Tamara Lekishvili, Francesca Malvezzi, Mariam Gachechiladze, Martin Behe, Victor Levitsky, Pamela A. Trail
Summary: The CD40 receptor is an attractive target for cancer immunotherapy. Researchers have developed a multispecific DARPin construct, alpha-FAPxCD40, which selectively activates CD40 at the site of disease and potently activates human antigen-presenting cells. In a mouse model, this construct showed significant anti-tumor activity without causing elevated blood cytokines or hepatotoxicity. These findings suggest that it may have a favorable therapeutic index in humans.
CANCER IMMUNOLOGY RESEARCH
(2022)
Article
Biochemistry & Molecular Biology
Giulia Valpreda, Belinda Trachsel, Viola Vogel, Roger Schibli, Linjing Mu, Martin Behe
Summary: In this study, dual renal brush border membrane (BBM) enzyme-sensitive Met-Val-Lys-based linkers were employed to reduce the renal retention of 111In-labelled FnBPs. The results showed that the dual MVK strategy significantly lowered the renal retention of 111In-labelled FnBPs, with minor influence on the biodistribution in other organs. These findings are crucial for the clinical translation of mechano-sensory FnBPs.
BIOORGANIC & MEDICINAL CHEMISTRY
(2022)
Letter
Oncology
Michal Grzmil, Paul Boersema, Ashish Sharma, Alain Blanc, Stefan Imobersteg, Martin Pruschy, Paola Picotti, Roger Schibli, Martin Behe
Summary: Our study compares the cellular responses to external beam radiation therapy (EBRT) and internal targeted radionuclide therapy (TRT). We found that TRT robustly activates signaling pathways in cancer cells, including EGFR, MAPKs, and integrin receptor. Inhibiting these pathways increases the sensitivity of cancer cells to radiolabeled minigastrin. In vivo experiments showed that EGFR inhibitor erlotinib enhances therapeutic response and prolongs the survival of nude mice.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yun Qin, Stefan Imobersteg, Stephan Frank, Alain Blanc, Tanja Chiorazzo, Philipp Berger, Roger Schibli, Martin P. Behe, Michal Grzmil
Summary: α-particle emitters have potential as therapeutic radionuclides, but toxicity and radioresistance limit their efficacy. This study identified the radiation-activated mechanisms driving cancer cell survival, providing opportunities for therapeutic interference to improve the efficacy and safety of α-particle therapy.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Review
Oncology
Michal Grzmil, Fabius Wiesmann, Roger Schibli, Martin Behe
Summary: Targeted radionuclide therapy (TRT) is a cancer treatment that delivers cancer-selective radiopharmaceuticals to destroy cancer cells without harming healthy tissue. This review focuses on the use of mTORC1 inhibition to improve the efficacy of TRT by delivering radiolabeled ligands. It discusses the rationale, efficacy, and safety of this combinatorial approach in cancer patients.
Review
Chemistry, Medicinal
Silvio Aime, Mohammed Al-Qahtani, Martin Behe, Guy Bormans, Giuseppe Carlucci, Jean N. DaSilva, Clemens Decristoforo, Adriano Duatti, Philip H. Elsinga, Klaus Kopka, Xiang-Guo Li, Zhibo Liu, Robert H. Mach, Oskar Middel, Jan Passchier, Marianne Patt, Ivan Penuelas, Ana Rey, Peter J. H. Scott, Sergio Todde, Jun Toyohara, Danielle Vugts, Zhi Yang
Summary: The Editorial Board releases highlight commentary to update readers on trends in radiopharmaceutical development, covering 23 different topics from novel radiochemistry to first in man application of novel radiopharmaceuticals, highlighting progress in the research field.
EJNMMI RADIOPHARMACY AND CHEMISTRY
(2021)
Article
Chemistry, Medicinal
Nic Gillings, Olaug Hjelstuen, Jim Ballinger, Martin Behe, Clemens Decristoforo, Philip Elsinga, Valentina Ferrari, Petra Kolenc Peitl, Jacek Koziorowski, Peter Laverman, Thomas L. Mindt, Oliver Neels, Meltem Ocak, Marianne Patt, Sergio Todde
Summary: This guideline for small-scale preparation of radiopharmaceuticals is based on the view of the Radiopharmacy Committee of EANM. It follows the format of EU GMP guidelines and is intended for non-commercial sites like hospital radiopharmacies, nuclear medicine departments, research PET centers, and healthcare establishments. The guideline aims to assist radiopharmacies in preparing safe diagnostic and therapeutic radiopharmaceuticals for human administration.
EJNMMI RADIOPHARMACY AND CHEMISTRY
(2021)
Review
Chemistry, Medicinal
Mohammed Al-Qahtani, Martin Behe, Guy Bormans, Giuseppe Carlucci, Jean Dasilva, Clemens Decristoforo, Philip H. Elsinga, Klaus Kopka, Xiang-Guo Li, Robert Mach, Oskar Middel, Jan Passchier, Marianne Patt, Ivan Penuelas, Ana Rey, Peter J. H. Scott, Sergio Todde, Jun Toyohara, Danielle Vugts
Summary: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to describe trends in the field, with 19 different topics selected by each member of the Editorial Board addressing various aspects from novel radiochemistry to first in man application of novel radiopharmaceuticals.
EJNMMI RADIOPHARMACY AND CHEMISTRY
(2021)